Aurora Private Wealth Inc. Makes New $943,000 Investment in Merck & Co., Inc. $MRK

Key Points

• Aurora Private Wealth Inc. initiated a new position in Merck, buying 8,961 shares worth about $943,000 in the fourth quarter, according to its 13F filing.
• Merck beat Q1 revenue and adjusted EPS expectations (Q1 revenue $16.29B) and set FY‑2026 guidance of $5.04–$5.16 EPS, but reported a GAAP loss from an acquisition‑related Cidara charge and noted competitive risks that could pressure longer‑term sales.
• The company posted several regulatory and pipeline wins — FDA approval of a 2‑drug HIV regimen, EC approval for an RSV prevention product, and Phase‑3 dosing for enpatoran in lupus — and analysts hold a consensus "Moderate Buy" with a target around $128.18.

Aurora Private Wealth Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,961 shares of the company's stock, valued at approximately $943,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. DLD Asset Management LP grew its position in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc grew its position in shares of Merck & Co., Inc. by 5.9% in the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock valued at $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. grew its position in shares of Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its position in shares of Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

Merck & Co., Inc. Trading Up 2.9%

Shares of MRK stock opened at $112.30 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market cap of $277.36 billion, a P/E ratio of 31.63, a price-to-earnings-growth ratio of 2.27 and a beta of 0.19. The stock has a 50 day simple moving average of $117.69 and a 200 day simple moving average of $107.54. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 26.84% and a net margin of 13.59%.The firm's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 4.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CMO Chirfi Guindo sold 10,000 shares of the business's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business's stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares of the company's stock, valued at approximately $2,583,278.39. This trade represents a 41.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 in the last quarter. Company insiders own 0.17% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on MRK shares. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research report on Friday, February 13th. TD Cowen upped their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research report on Tuesday, January 20th. Citigroup upped their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a "neutral" rating in a research report on Friday, March 20th. Wolfe Research raised Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price on the stock in a research report on Thursday, January 8th. Finally, Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.